Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | OSBP | P22059 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.54 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 12/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565022 | 0.88 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8159169 | 0.84 | OSBP (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4430724 | 0.84 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL743933 | 0.83 | USP2 (0.61) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL12274582 | 0.83 | USP2 (0.61) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18797660 | 0.82 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2638134 | 0.82 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL6060845 | 0.82 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27975861 | 0.82 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963054 | 0.82 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2019-02-14 | — | — | US | disclosed |
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2342616-A2 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | Alnylam Pharmaceuticals Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010039548-A2 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | USP2 4435/4885CYP46A1 3464/4885LMNA 4253/4885 |
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | USP2 4435/4885CYP46A1 3464/4885LMNA 4253/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | USP2 4435/4885CYP46A1 3464/4885LMNA 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.